BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26646755)

  • 1. TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
    Koehler K; Liebner D; Chen JL
    Ann Oncol; 2016 Mar; 27(3):539-43. PubMed ID: 26646755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
    Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
    Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
    Kasper B; Sleijfer S; Litière S; Marreaud S; Verweij J; Hodge RA; Bauer S; Kerst JM; van der Graaf WTA
    Ann Oncol; 2014 Mar; 25(3):719-724. PubMed ID: 24504442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
    Fu S; Hou MM; Naing A; Janku F; Hess K; Zinner R; Subbiah V; Hong D; Wheler J; Piha-Paul S; Tsimberidou A; Karp D; Araujo D; Kee B; Hwu P; Wolff R; Kurzrock R; Meric-Bernstam F
    Ann Oncol; 2015 May; 26(5):1012-1018. PubMed ID: 25669829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.
    Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong D; Kurzrock R
    Mol Cancer Ther; 2016 Oct; 15(10):2475-2485. PubMed ID: 27466356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
    Wang Y; Janku F; Piha-Paul S; Hess K; Broaddus R; Liu L; Shi N; Overman M; Kopetz S; Subbiah V; Naing A; Hong D; Tsimberidou AM; Karp D; Yao J; Fu S
    Sci Rep; 2020 Feb; 10(1):3080. PubMed ID: 32080210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
    Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
    BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup.
    Kawai A; Araki N; Hiraga H; Sugiura H; Matsumine A; Ozaki T; Ueda T; Ishii T; Esaki T; Machida M; Fukasawa N
    Jpn J Clin Oncol; 2016 Mar; 46(3):248-53. PubMed ID: 26864131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.
    Duffaud F; Sleijfer S; Litière S; Ray-Coquard I; Le Cesne A; Papai Z; Judson I; Schöffski P; Chawla SP; Dewji R; Marreaud S; Verweij J; van der Graaf WT
    Eur J Cancer; 2015 Nov; 51(17):2615-23. PubMed ID: 26321011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
    Coens C; van der Graaf WT; Blay JY; Chawla SP; Judson I; Sanfilippo R; Manson SC; Hodge RA; Marreaud S; Prins JB; Lugowska I; Litière S; Bottomley A
    Cancer; 2015 Sep; 121(17):2933-41. PubMed ID: 26033286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
    Bupathi M; Hays JL; Chen JL
    PLoS One; 2017; 12(11):e0188116. PubMed ID: 29141017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).
    Grande E; Capdevila J; Castellano D; Teulé A; Durán I; Fuster J; Sevilla I; Escudero P; Sastre J; García-Donas J; Casanovas O; Earl J; Ortega L; Apellaniz-Ruiz M; Rodriguez-Antona C; Alonso-Gordoa T; Díez JJ; Carrato A; García-Carbonero R
    Ann Oncol; 2015 Sep; 26(9):1987-1993. PubMed ID: 26063633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pazopanib, a new therapy for metastatic soft tissue sarcoma.
    Verweij J; Sleijfer S
    Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
    Sleijfer S; Ray-Coquard I; Papai Z; Le Cesne A; Scurr M; Schöffski P; Collin F; Pandite L; Marreaud S; De Brauwer A; van Glabbeke M; Verweij J; Blay JY
    J Clin Oncol; 2009 Jul; 27(19):3126-32. PubMed ID: 19451427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
    Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE
    Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
    Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma.
    Kim SK; Kim JH; Kim SH; Lee YH; Han JW; Baek W; Woo HY; Jeon MK; Kim HS
    BMC Cancer; 2021 Mar; 21(1):336. PubMed ID: 33789622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study
    Gelderblom H; Judson IR; Benson C; Merimsky O; Grignani G; Katz D; Freivogel KW; Stein D; Jobanputra M; Mungul A; Manson SC; Sanfilippo R
    Acta Oncol; 2017 Dec; 56(12):1769-1775. PubMed ID: 28723233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacological profile and clinical results in advanced soft tissue sarcoma patients of pazopanib hydrochloride (Votrient(®))].
    Arai H; Fukasawa N; Ueta F
    Nihon Yakurigaku Zasshi; 2013 Jan; 141(1):37-42. PubMed ID: 23302947
    [No Abstract]   [Full Text] [Related]  

  • 20. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
    Kollár A; Jones RL; Stacchiotti S; Gelderblom H; Guida M; Grignani G; Steeghs N; Safwat A; Katz D; Duffaud F; Sleijfer S; van der Graaf WT; Touati N; Litière S; Marreaud S; Gronchi A; Kasper B
    Acta Oncol; 2017 Jan; 56(1):88-92. PubMed ID: 27838944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.